Idera Pharmaceuticals, Inc.

364 articles with Idera Pharmaceuticals, Inc.

• Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results

  8/9/2022

  Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2022.

• 

  Clinical Catch-Up: Amgen, AstraZeneca, Avillion Attack Asthma

  5/23/2022

  Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.

• Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC– Enrollment Stopped Early for Efficacy –

  5/17/2022

  Idera Pharmaceuticals, Inc. (“Idera,” “we,” and “our”) (Nasdaq: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, regarding its investigator-sponsored trial, INTRIM 1, involving tilsotolimod, Idera’s synthetic Toll-like receptor 9 agonist.

• 

  Idera Halts Enrollment For Melanoma Trial Following Positive Early Data

  5/17/2022

  Idera Pharmaceuticals has stopped patient enrollment early for its Phase II trial on a candidate melanoma drug after interim data delivered impressive results.

• Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

  5/5/2022

  Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2022.

• Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

  3/31/2022

  Idera Pharmaceuticals, Inc. reported its financial and operational results for the fourth quarter and year ended December 31, 2021.

• Idera Pharmaceuticals Announces Tilsotolimod Updates

  12/14/2021

  Idera Pharmaceuticals, Inc. announced clinical updates regarding tilsotolimod, its synthetic Toll-like receptor 9 agonist.

• Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

  11/8/2021

  Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended September 30, 2021.

• Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

  8/9/2021

  Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2021.

• Idera Pharmaceuticals Announces Corporate Updates

  5/18/2021

  Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today announced that it will not continue ILLUMINATE-301, the Company’s trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, to its overall survival (OS) primary endpoint.

• Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

  4/29/2021

  Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2021.

• 

  Idera’s Melanoma Candidate Hits Snag in Phase III Trial

  3/19/2021

  A Phase III trial from Idera Pharmaceuticals did not reach the primary endpoint of ORR in patients with anti-PD-1 refractory advanced melanoma treated with a combination regimen comprising ipilimumab and the company’s investigational agent tilsotolimod.

• Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma– Objective Response Rate Endpoint Not Met –

  3/18/2021

  Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today is announcing that ILLUMINATE-301, the Company’s pivotal registration trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, did not meet its primary endpoint of objective response rate (ORR)

• Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate UpdateILLUMINATE-301 Continues on Track for Data Later this Month

  3/1/2021

  Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2020.

• Idera Pharmaceuticals to Present at Upcoming Conferences - Jan 11, 2021

  1/11/2021

  Idera Pharmaceuticals, Inc. announced that it will provide a company outlook for 2021 at upcoming conferences.

• Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million

  12/15/2020

  Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the “Purchase Agreement”), resulting in aggregate proceeds of up to $20.7 million in common stock and warrant investment by funds affiliated with an institutional investor.

• Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer

  11/17/2020

  Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; “Idera”) today announced that Daniel Soland will join Idera on January 4, 2021, as Senior Vice President and Chief Operating Officer (COO).

• Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate UpdateILLUMINATE-301 Continues on Track and Beyond Melanoma Strategy Advances

  10/29/2020

  Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended September 30, 2020. “Tilsotolimod is the most advanced TLR-9 agonist therapy in development, and we have made tremendous strides against our objectives for 2020,” stated Vincent Milano, Idera’s Chief Executive Officer. “We continue to work diligently against our timelines for ILLUMINATE-301, which

• Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037– Protects Method-of-Use in CRC and HNSCC –

  9/28/2020

  Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,772,907 (the ‘907 Patent) and allowed U.S. Patent Application No. 16/557,597 (the ‘597 Application), both entitled “Immune Modulation with TLR9 Agonists for Cancer Treatment” and each of which includes the Company’s investigational therapy tilsotolimod.

• Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020

  9/15/2020

  Final data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presented AbbVie to present a trial-in-progress poster of ABBV-368 in combination with tilsotolimod in recurrent / metastatic head and neck squamous cell carcinoma (HNSCC) Idera also to present at H.C. Wainwright 22nd Annual Global Investment Conference EXTON, Pa., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA)